Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FRONTIER DNA methylation

ABSTRACT: Tumor biopsies profiled by DNA methylation array

PROVIDER: EGAD00010002182 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Spatial concordance of DNA methylation classification in diffuse glioma.

Verburg Niels N Barthel Floris P FP Anderson Kevin J KJ Johnson Kevin C KC Koopman Thomas T Yaqub Maqsood M MM Hoekstra Otto S OS Lammertsma Adriaan A AA Barkhof Frederik F Pouwels Petra J W PJW Reijneveld Jaap C JC Rozemuller Annemieke J M AJM Beliën Jeroen A M JAM Boellaard Ronald R Taylor Michael D MD Das Sunit S Costello Joseph F JF Vandertop William Peter WP Wesseling Pieter P de Witt Hamer Philip C PC Verhaak Roel G W RGW

Neuro-oncology 20211201 12

<h4>Background</h4>Intratumoral heterogeneity is a hallmark of diffuse gliomas. DNA methylation profiling is an emerging approach in the clinical classification of brain tumors. The goal of this study is to investigate the effects of intratumoral heterogeneity on classification confidence.<h4>Methods</h4>We used neuronavigation to acquire 133 image-guided and spatially separated stereotactic biopsy samples from 16 adult patients with a diffuse glioma (7 IDH-wildtype and 2 IDH-mutant glioblastoma ...[more]

PMID: 34049406

Similar Datasets

Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay

Project description:Epigenomics is developing a colon cancer screening assay based on differential methylation of specific CpG sites for the detection of early stage disease. A genome-wide methylation analysis and oligonucleotide array study using DNA from various stages of colon cancer and normal tissue have been completed to obtain candidate CpG markers. Based on results obtained in the above studies, Epigenomics has moved to the final stages of feasibility with a specific, highly sensitive real-time marker assay that is able to detect colon cancer DNA in blood plasma.

| 2056787 | ecrin-mdr-crc

Papillary Tumor of the Pineal Region: analysis of DNA methylation profiles and clinical outcomes in 76 cases

Project description:Genomewide DNA methylation array profiling and analysis of 76 new and public published Papillary Tumor of the Pineal Region (PTPR). The methylation idat profiles of 39 newly profiled tumors were provided here.

2024-07-19 | GSE254031 | GEO

DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer

Project description:Genome wide DNA methylation profiling of normal and tumor prostate samples, as well as cultured primary prostate cells overexpressing DNA Methyltransferases (DNMTs) and EZH2 Candidate gene based studies have identified a handful of aberrant CpG DNA methylation events in prostate cancer. However, DNA methylation profiles have not been compared on a large scale between prostate tumor and normal prostate, and the mechanisms behind these alterations are unknown. In this study, we quantitatively profiled 95 primary prostate tumors and 86 healthy prostate tissue samples for their DNA methylation levels at 26,333 CpGs representing 14,104 gene promoters by using the Illumina HumanMethylation27 platform. A 2-class Significance Analysis of this dataset revealed 5,912 CpG sites with increased DNA methylation and 2,151 CpG sites with decreased DNA methylation in tumors (FDR < 0.8%). Prediction Analysis of this dataset identified 87 CpGs that are the most predictive diagnostic methylation biomarkers of prostate cancer. By integrating available clinical follow-up data, we also identified 69 prognostic DNA methylation alterations that correlate with biochemical recurrence of the tumor. To identify the mechanisms responsible for these genome-wide DNA methylation alterations, we measured the gene expression levels of several DNA methyltransferases (DNMTs) and their interacting proteins by TaqMan qPCR and observed increased expression of DNMT3A2, DNMT3B, and EZH2 in tumors. Subsequent transient transfection assays in cultured primary prostate cells revealed that DNMT3B1 and DNMT3B2 overexpression resulted in increased methylation of a substantial subset of CpG sites that also showed tumor-specific increased methylation.

2011-04-19 | GSE26126 | GEO

DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer

2011-04-19 | E-GEOD-26126 | biostudies-arrayexpress

Intra-Tumor DNA Methylation Heterogeneity in Glioblastoma; Implications for DNA Methylation-based Classification

Project description:Background: A feature of glioblastoma (GBM) is the cellular and molecular heterogeneity, both within and between tumors. This variability results in a risk for sampling bias and potential tumor escape from future targeted therapy. Heterogeneous gene expression within GBM is well documented, but little is known regarding the epigenetic heterogeneity. We therefore aimed to profile the intra-tumor DNA methylation heterogeneity in GBM. Methods: 3-4 biopsies per tumor from spatially separated regions were collected from 12 GBM patients. We performed genome-wide DNA methylation analysis (~850,000 CpG sites) and compared inter- and intra-tumor variation. Results: All samples were classified as GBM IDH wt or IDH mutated by DNA methylation profiling, but the GBM subtype differed within five tumors. Some GBM samples exhibited higher DNA methylation differences within tumors than between, and many CpG sites (mean: 17,000) had different methylation levels within the tumors. Conclusions: We demonstrated that intra-tumor DNA methylation heterogeneity is a feature of GBM. Although all biopsies were classified as GBM IDH wt/mutated by DNA methylation analysis, the assigned subtype differed in samples from the same patient. The observed DNA methylation heterogeneity within tumors is important to consider for methylation-based biomarkers and future improvements in stratification of GBM patients.

2019-02-27 | GSE116298 | GEO

Assessment of DNA methylation patterns related to ankylosing spondylitis

Project description:The aim of this study was to seek more novel ankylosing spondylitis (AS)-associated DNA methylation. Genome wide DNA methylation profiling was profiled in peripheral blood mononuclear cells (PBMCs) from 24 individuals (AS: health controls (HCs) = 12:12) with high-throughput array. The Illumina Infinium MethylationEPIC Array was used to assess these genome-wide methylation patterns.

2022-01-11 | GSE179571 | GEO

DNA methylation array analysis of human gastrointestinal organoids and Intestinal Metaplasia (IM) organoids

Project description:Using DNA methylation array, we profiled epigentic changes of human gastric, intestinal and IM organoids.

2024-10-15 | GSE210994 | GEO

Tumor DNA methylation in pediatric germ cell tumors

Project description:Epigenomewide methylation profiling of tumor DNA from pediatric germ cell tumors by sex, tumor histology, tumor location and age at diagnosis. DNA methylation was measured using the Illumina Infinium HumanMethylation450 array

2021-09-11 | GSE183798 | GEO

: Arginine methylation of BRD4 by PRMT2/4 governs transcription and DNA repair

Project description:BRD4 functions as an epigenetic reader and plays a crucial role in regulating transcription and genome stability. Dysregulation of BRD4 is frequently observed in various human cancers. However, the molecular details of BRD4 regulation remain largely unknown. Here, we report that PRMT2- and PRMT4-mediated arginine methylation is pivotal for BRD4-dependent transcription, DNA repair, and tumor growth. Specifically, PRMT2/4 interact with and methylates BRD4 at R179, R181, and R183. This arginine methylation selectively controls a transcriptional program by promoting BRD4 enrichment at the hyper-acetylated chromatin regions. Moreover, BRD4 arginine methylation is induced by DNA damage and thereby promotes its binding to chromatin for DNA repair. Deficiency in BRD4 arginine methylation significantly suppresses tumor growth and sensitizes cells to BET inhibitors and DNA damaging agents. Therefore, our findings reveal an arginine methylation-dependent regulatory mechanism of BRD4 function and highlight targeting PRMT2/4 for better anti-tumor effect of BET inhibitors and DNA damaging agents.

2023-03-11 | PXD034650 | Pride

Whole blood DNA methylation arrays of individuals with Sotos syndrome and healthy control subjects

Project description:To understand how NSD1 inactivation deregulates DNA methylation, and to explore how these abnormalities affect human development, we profiled DNA methylation in SS patients and healthy control individuals using the Illumina Infinium EPIC Beadchip array.

2022-03-01 | GSE191276 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data